Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 44, 2010, Pages 18979-18984

  Wang, Taia T ^a   Tan, Gene S ^a   Hai, Rong ^a   Pica, Natalie ^a   Ngai, Lily ^a   Ekiert, Damian C ^b   Wilson, Ian A ^b   García Sastre, Adolfo ^a   Moran, Thomas M ^a   Palese, Peter ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

HA2; Mice; Pandemic; Synthetic peptide; Vaccine

Indexed keywords

12D1 ANTIBODY; ANTIBODY; HEMAGGLUTININ; HEMAGGLUTININ ANTIBODY; HEMAGGLUTININ SUBUNIT 2 PROTEIN; INFLUENZA VACCINE; LAH KLH VACCINE; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ALPHA HELIX; ANIMAL EXPERIMENT; ANIMAL MODEL; BINDING SITE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG PROTEIN BINDING; IN VIVO STUDY; INFLUENZA A (H1N1); INFLUENZA A (H3N2); INFLUENZA A (H5N1); INFLUENZA VACCINATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS NEUTRALIZATION;

MUS; ORTHOMYXOVIRIDAE;

EID: 78649953803     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1013387107     Document Type: Article

References (22)

1. Bommakanti G, et al. (2010) Design of an HA2-based Escherichia coli expressed influenza immunogen that protects mice from pathogenic challenge. Proc Natl Acad Sci USA 107:13563-13564.
2. Steel J, et al (2010) Influenza virus vaccine based on the conserved hemagglutinin stalk domain. MBio 1(1):1-9.
3. Wang TT, et al. (2010) Broadly protective monoclonal antibodies against H3 influenzaviruses following sequential immunization with different hemagglutinins. PLoS Pathog 6:e1000796.
4. Wei CJ, et al. (2010) Induction of broadly neutralizing H1N1 influenza antibodies byvaccination. Science 329(5995):1060-1064.
5. Wilson IA, Skehel JJ, Wiley DC (1981) Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 A resolution. Nature 289:366-373.
6. Palese P, Shaw M (2007) Fieldś Virology (Lippincott Williams & Wilkins, Philadelphia), 5th Ed.
7. Throsby M, et al. (2008) Heterosubtypic neutralizing monoclonal antibodies crossprotective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS ONE 3:e3942.
8. Sui J, et al. (2009) Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 16:265-273.
9. Ekiert DC, et al. (2009) Antibody recognition of a highly conserved influenza virus epitope. Science 324:246-251.
10. Werle M, Bernkop-Schnürch A (2006) Strategies to improve plasma half life time of peptide and protein drugs. Amino Acids 30:351-367.
11. Jumper MD, Splawski JB, Lipsky PE, Meek K (1994) Ligation of CD40 induces sterile transcripts of multiple Ig H chain isotypes in human B cells. J Immunol 152:438-445.
12. Steel J, et al. (2009) Live attenuated influenza viruses containing NS1 truncationsas vaccine candidates against H5N1 highly pathogenic avian influenza. J Virol 83:1742-1753.
13. Moltedo B, et al. (2009) Cutting edge: Stealth influenza virus replication precedesthe initiation of adaptive immunity. J Immunol 183:3569-3573.
14. Hermesh T, Moltedo B, Moran TM, López CB (2010) Antiviral instruction of bone marrow leukocytes during respiratory viral infections. Cell Host Microbe 7:343-353.
15. Centers for Disease Control and Prevention (2008) Update: influenza activity-UnitedStates, September 30, 2007-April 5, 2008, and composition of the 2008-09 influenza vaccine. MMWR Morb Mortal Wkly Rep 57(15):404-409.
16. Chen J, Skehel JJ, Wiley DC (1999) N- and C-terminal residues combine in the fusionpH influenza hemagglutinin HA(2) subunit to form an N cap that terminates the triple-stranded coiled coil. Proc Natl Acad Sci USA 96:8967-8972.
17. Kwong PD, Wilson IA (2009) HIV-1 and influenza antibodies: Seeing antigens in new ways. Nat Immunol 10:573-578.
18. Khurana S, et al. (2009) Antigenic fingerprinting of H5N1 avian influenza using convalescent sera and monoclonal antibodies reveals potential vaccine and diagnostic targets. PLoS Med 6:e1000049.
19. Tritto E, Mosca F, De Gregorio E (2009) Mechanism of action of licensed vaccine adjuvants. Vaccine 27:3331-3334.
20. Subbarao K, Murphy BR, Fauci AS (2006) Development of effective vaccines against pandemic influenza. Immunity 24:5-9.
21. Towbin H, Staehelin T, Gordon J (1979) Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applications. Proc Natl Acad Sci USA 76:4350-4354.
22. Basler CF, et al. (2001) Sequence of the 1918 pandemic influenza virus nonstructural gene (NS) segment and characterization of recombinant viruses bearing the 1918 NS genes. Proc Natl Acad Sci USA 98:2746-2751.